Mount Sinai Hospital in New York has deployed FloPatch, Flosonics’ wireless Doppler ultrasound device, in its surgical and transplant ICU. This marks Flosonics’ first East Coast U.S. adoption and expands its footprint in critical care.
FloPatch is an FDA-cleared, non-invasive wearable device enabling rapid, repeatable bedside hemodynamic assessments to guide intravenous fluid management. It helps identify patients unresponsive to fluids, avoiding complications from unnecessary treatments.
Early data showed 42% of patients assessed with FloPatch were fluid unresponsive, allowing tailored care. Flosonics’ CMO Dr. Jon-Emile Kenny emphasized the device’s role in broadening ultrasound use beyond physicians to frontline ICU staff.
Mount Sinai’s adoption highlights its leadership in precision medicine and critical care innovation.
Follow MEDWIRE.AI for updates on ICU technology and fluid management advancements.
